XNCR logo

XNCR
Xencor Inc

767
Mkt Cap
$831.87M
Volume
3,780.00
52W High
$18.69
52W Low
$6.92
PE Ratio
-4.88
XNCR Fundamentals
Price
$11.22
Prev Close
$11.88
Open
$11.66
50D MA
$12.28
Beta
1.43
Avg. Volume
749,493.07
EPS (Annual)
-$1.24
P/B
1.61
Rev/Employee
$482,984.61
$776.61
Loading...
Loading...
News
all
press releases
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...
Business Wire·46m ago
News Placeholder
More News
News Placeholder
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -164.58% and -75.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Xencor Reports First Quarter 2026 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the...
Business Wire·12d ago
News Placeholder
Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026
Xencor (NASDAQ:XNCR) used a webcast during Digestive Disease Week 2026 to highlight Phase I results for its TL1A-targeting monoclonal antibody XmAb942 and to outline preclinical data supporting...
MarketBeat·12d ago
News Placeholder
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the...
Business Wire·14d ago
News Placeholder
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
Xencor (XNCR) Projected to Post Earnings on Wednesday
Xencor (NASDAQ:XNCR) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-xencor-inc-stock...
MarketBeat·19d ago
News Placeholder
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assig...
MarketBeat·19d ago
News Placeholder
Xencor (NASDAQ:XNCR) Stock Price Down 8% - Should You Sell?
Xencor (NASDAQ:XNCR) Shares Down 8% - Here's What Happened...
MarketBeat·20d ago
News Placeholder
Xencor (NASDAQ:XNCR) Stock Passes Above 50 Day Moving Average - Time to Sell?
Xencor (NASDAQ:XNCR) Stock Price Passes Above 50-Day Moving Average - What's Next...
MarketBeat·20d ago
<
1
2
...
>

Latest XNCR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.